COVAX - Time to reconsider the strategy and its target
- PMID: 37073303
- PMCID: PMC10098302
- DOI: 10.1016/j.hpopen.2023.100096
COVAX - Time to reconsider the strategy and its target
Abstract
COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion US dollars already committed. While some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. First, mass COVID-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. Second, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. We conclude that the COVAX initiative warrants urgent review.
© 2023 The Author(s).
Conflict of interest statement
Elisabeth Paul (last/corresponding author) is an active member of the Technical Review Panel of the Global Fund and of the Independent Review Committee of Gavi. However, this paper was written in total independence from these institutions. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
COVAX and COVID-19 Vaccine Inequity: A case study of G-20 and African Union.Public Health Chall. 2024 May 9;3(2):e185. doi: 10.1002/puh2.185. eCollection 2024 Jun. Public Health Chall. 2024. PMID: 40496165 Free PMC article.
-
Business as Usual? Centering Human Rights to Advance Global COVID-19 Vaccine Equity Through COVAX.Health Hum Rights. 2022 Dec;24(2):219-228. Health Hum Rights. 2022. PMID: 36579321 Free PMC article.
-
COVAX, vaccine donations and the politics of global vaccine inequity.Global Health. 2022 Mar 5;18(1):26. doi: 10.1186/s12992-022-00801-z. Global Health. 2022. PMID: 35248116 Free PMC article.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence.Vaccines (Basel). 2023 Feb 3;11(2):347. doi: 10.3390/vaccines11020347. Vaccines (Basel). 2023. PMID: 36851226 Free PMC article. Review.
Cited by
-
The devil's in the detail: an appraisal of the use of innovative financing mechanisms for pandemic prevention, preparedness and response.Global Health. 2025 Mar 27;21(1):13. doi: 10.1186/s12992-025-01103-w. Global Health. 2025. PMID: 40148959 Free PMC article.
-
Experiences, Enablers, and Challenges in Service Delivery and Integration of COVID-19 Vaccines: A Rapid Systematic Review.Vaccines (Basel). 2023 May 11;11(5):974. doi: 10.3390/vaccines11050974. Vaccines (Basel). 2023. PMID: 37243078 Free PMC article. Review.
References
-
- World Health Organization. COVAX - Working for global equitable access to COVID-19 vaccines [Internet]. 2022 [cited 2022 Jan 19]. Available from: https://www.who.int/initiatives/act-accelerator/covax.
-
- World Health Organization. WHO releases global COVID-19 vaccination strategy update to reach unprotected [Internet]. 2022 [cited 2023 Jan 5]. Available from: https://www.who.int/news/item/22-07-2022-who-releases-global-covid-19-va.... - PMC - PubMed
-
- World Health Organization. Access to COVID-19 tools funding commitment tracker [Internet]. 2022 [cited 2023 Jan 6]. Available from: https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker.
-
- The Global Fund. Seventh Replenishment - Fight for What Counts [Internet]. 2022 [cited 2023 Jan 6]. Available from: https://www.theglobalfund.org/en/seventh-replenishment/.
-
- Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J, et al. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open [Internet]. 2022;12(9). Available from: https://bmjopen.bmj.com/content/12/9/e061752. - PMC - PubMed
LinkOut - more resources
Full Text Sources